Table 1.
Baseline characteristics
| Characteristic, n (%) | Everolimus plus letrozole (n = 20) | FEC (n = 20) |
|---|---|---|
| Age, year | ||
| Median (range) | 60.0 (54.0–70.0) | 56.5 (51.0–66.0) |
| ER status | ||
| Positive | 20 (100.0) | 20 (100.0) |
| Negative | 0 (0.0) | 0 (0.0) |
| PR status | ||
| Positive | 19 (95.0) | 14 (70.0) |
| Negative | 1 (5.0) | 6 (30.0) |
| T stage | ||
| T1 | 2 (10.0) | 1 (5.0) |
| T2 | 13 (65.0) | 15 (75.0) |
| T3/T4 | 5 (25.0) | 4 (20.0) |
| N stage | ||
| N0 | 9 (45.0) | 8 (40.0) |
| N1 | 11 (55.0) | 12 (60.0) |
| Histological type | ||
| Ductal | 12 (60.0) | 17 (85.0) |
| Lobular | 3 (15.0) | 0 (0.0) |
| Other/unknown | 5 (25.0) | 3 (15.0) |
| Ki67 expression | ||
| < 20% | 10 (50.0) | 5 (25.0) |
| ≥ 20% | 10 (50.0) | 15 (75.0) |
Data were presented as median (range) or No. (%). FEC Fluorouracil, epirubicin plus cyclophosphamide, ER Estrogen receptor, PR Progesterone receptor